Paolo Tarantino: Glad to have had Giacomo De Micheli at Dana-Farber’s Breast Oncology Center / cancer, DFCI, OncoDaily, Oncology, Paolo Tarantino, Sara Tolaney

Paolo Tarantino Highlights ESMO Breast 25 as ESMO Ambassador / Breast Cancer, cancer, ESMO, ESMO Ambassadors, ESMO Breast 25, OncoDaily, Oncology, Paolo

Paolo Tarantino: ADCs are rapidly moving to earlier line treatment for breast cancer / Breast Cancer, cancer, Dana-Farber Cancer Institute, OncoDaily,

Paolo Tarantino, MD, discusses adjuvant strategies, trial data, and risk stratification shaping HER2+ breast cancer care.

Paolo Tarantino: St. Gallen Consensus 2025 - 10 key votes / Breast Cancer, breast oncology, cancer, Dana-Farber Cancer Institute, fight against cancer, G

Paolo Tarantino: A pleasure to join the gender balance session at JSMO25 / cancer, JSMO25, OncoDaily, Oncology, Paolo Tarantino

Paolo Tarantino: Upcoming SABCS24 session on the future of ADCs / cancer, OncoDaily, Oncology, Paolo Tarantino, SABCS 2024

Along with the Oncology Brothers, Paolo Tarantino, MD, elaborates on the San Antonio Breast Cancer Symposium (SABCS) 2022 analysis, which identified the duration of prior CDK4/6 inhibitor (CDK4/6i) th...

Bluesky is the lobby to the open web. Find and build your community here.

Operable gastrooesophageal adenocarcinoma (GOA) is treated with multimodality therapy which is curative in <50% of patients. Patients in the UK with o…

Abstract. Antibody–drug conjugates (ADC) represent one of the most rapidly expanding treatment modalities in oncology, with 11 ADCs approved by the FDA and more than 210 currently being tested in clin...